Indiana University

Assembly Biosciences, Inc.

Samson Francis

Lee Daniel Arnold

Hans Maag

Leping Li

Mark G Bures

Simon Nicolas Haydar

William W Turner

William Wilson Turner, Jr

Adam Zlotnick

Roopa Rai

Lichun Li

Simon Haydar

William Turner

Mark Bures

The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

Hepatitis b core protein modulators

The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.

Cyclic sulfamide compounds and methods of using same

Hepatitis B core protein modulators

Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.

Hepatitis B viral assembly effectors

Growing community of inventors

Indianapolis, IN, United States of America

Samson Francis